Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0EP7M)

• Drug Name: Minaprine Drug Info
• Synonyms: Brantur; Cantor; Minaprina; Minaprinum; Minaprine dihydrochloride; AGR 1240; CB 30038; Cantor (TN); Minaprina [INN-Spanish]; Minaprinum [INN-Latin]; Minaprine (USAN/INN); Minaprine [USAN:BAN:INN]; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 4199
  ChEBI ID: CHEBI:51038
  CAS Number: CAS 25905-77-5
  TTD Drug ID: DM0EP7M
  INTEDE Drug ID: DR1093

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[4]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[5]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[6]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[7]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[8]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[9]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[9]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[9]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[9]
Pyrimidine derivative 27	DMIQSDW	N. A.	N. A.	Patented	[9]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[10]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[11]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[12]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[15]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[16]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[17]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[18]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[3]

References

• [1] Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2006 Jan;15(1):1-12.
• [2] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [3] Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem. 2003 Dec 1;11(24):5545-54.
• [4] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [5] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [6] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [7] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [8] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [9] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [10] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [11] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [12] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [15] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [16] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [17] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [18] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [19] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.